Status | Study |
Not yet recruiting |
Study Name: A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN Condition: C3 Glomerulonephritis Dense Deposit Disease Date: 2017-04-12 Interventions: Drug: ACH-0144471 ACH-0144471 will be administered to all patients enrolled in the study. |
Not yet recruiting |
Study Name: Daratumumab in Treatment of PGNIMD and C3 GN Condition: Membranoproliferative Glomerulonephritis Date: 2017-03-20 Interventions: Drug: Daratumumab Open-label Other Name: Darzalex |
Active, not recruiting |
Study Name: Eculizumab in Primary MPGN Condition: Membranoproliferative Glomerulonephritis Date: 2014-03-17 Interventions: Drug: Eculizumab Other Name: Soliris |
Terminated |
Study Name: Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease Condition: Dense Deposit Disease Membranoproliferative Glomerulonephritis Date: 2013-01-29 Interventions: Drug: CDX-1135 Other Names: TP10 sCR1 |
Completed |
Study Name: Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy Condition: Dense Deposit Disease Membranoproliferative Glomerulonephritis Date: 2010-10-13 Interventions: Drug: Eculizumab 900 mg IV once a week x 4 weeks, 1200 mg |
Completed |
Study Name: Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis Condition: Glomerulonephritis, Membranoproliferative Date: 2006-01-10 Interventions: Drug: Rituximab The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses |